Related Experiment Video

Updated: Dec 8, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.2K

PARP inhibition in treatment of pancreatic cancer

Pascal Hammel1, Chen Zhang1, Julia Matile1

  • 1Departments of Digestive and Medical Oncology, Hôpital Beaujon (AP-HP, Clichy) and Paris University , France.

Expert Review of Anticancer Therapy
|September 16, 2020
PubMed
Abstract

Insights

Olaparib is an effective maintenance therapy for metastatic pancreatic cancer patients with BRCA mutations. This targeted therapy improves outcomes after initial chemotherapy, offering a new treatment option.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Metastatic pancreatic ductal adenocarcinoma (PDAC) treatment has improved with polychemotherapies.
  • Novel therapeutic targets are crucial for effective maintenance therapies in PDAC.
  • PDAC patients with BRCA mutations show sensitivity to platinum agents.

Purpose of the Study:

  • To evaluate olaparib as a maintenance therapy for metastatic PDAC.
  • To assess the efficacy and tolerability of olaparib in patients with germline BRCA1/2 mutations.

Main Methods:

  • The POLO study investigated olaparib maintenance therapy.
  • Patients received platinum-based induction chemotherapy.
  • Inclusion criteria required germline BRCA1/2 mutations and controlled metastatic PDAC.

Main Results:

  • Olaparib demonstrated efficiency as a maintenance therapy.
  • Olaparib was well-tolerated in the studied patient population.
  • The study supports targeted maintenance therapy for specific PDAC subtypes.

Conclusions:

  • Olaparib is effective for maintenance therapy in metastatic PDAC with BRCA germline mutations.
  • Targeted maintenance therapy represents a significant advancement for PDAC treatment.
  • Further research is needed on PARP inhibitors in earlier PDAC stages and resistance mechanisms.
Keywords:
BRCA geneCancerPARPolaparibpancreasparp inhibitor

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.2K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K